The 23 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 75.00, with a high estimate of 100.00 and a low estimate of 63.00. The median estimate represents a +6.38% increase from the last price of 70.51.
The current consensus among 30 polled investment analysts is to Hold stock in Gilead Sciences Inc. This rating has held steady since January, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $1.53
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.